Millennium Management LLC Makes New $262,000 Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Millennium Management LLC purchased a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 151,614 shares of the company's stock, valued at approximately $262,000. Millennium Management LLC owned about 0.07% of Taysha Gene Therapies at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ground Swell Capital LLC bought a new position in Taysha Gene Therapies during the 4th quarter valued at approximately $25,000. Cibc World Markets Corp purchased a new stake in Taysha Gene Therapies during the fourth quarter valued at $28,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the 4th quarter worth approximately $31,000. Hsbc Holdings PLC grew its position in shares of Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after acquiring an additional 8,076 shares during the period. Finally, AXQ Capital LP bought a new stake in Taysha Gene Therapies during the fourth quarter valued at about $39,000. Hedge funds and other institutional investors own 77.70% of the company's stock.

Insider Activity

In related news, major shareholder Paul B. Manning purchased 750,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were purchased at an average cost of $2.75 per share, with a total value of $2,062,500.00. Following the purchase, the insider now owns 2,841,704 shares of the company's stock, valued at $7,814,686. This represents a 35.86% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, June 3rd. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a research report on Thursday, May 29th. Finally, Chardan Capital lifted their price target on shares of Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $7.57.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock traded down $0.02 during trading hours on Thursday, hitting $2.65. The company's stock had a trading volume of 4,230,552 shares, compared to its average volume of 3,085,864. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The company has a 50 day moving average of $2.12 and a 200 day moving average of $1.93. Taysha Gene Therapies, Inc. has a 12-month low of $1.05 and a 12-month high of $4.32. The stock has a market cap of $568.85 million, a PE ratio of 4.21 and a beta of 1.04.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same quarter last year, the business earned ($0.10) earnings per share. On average, sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.